Hybrid PET/optical imaging of integrin $\alpha_V\beta_3$ receptor expression using a $^{64}$Cu-labeled streptavidin/biotin-based dimeric RGD peptide

Choong Mo Kang$^{1,2}$, Hyun-Jung Koo$^1$, Gwang Il An$^3$, Yeon Seong Choe$^{1,2,}\ast$, Joon Young Choi$^1$, Kyung-Han Lee$^{1,2}$ and Byung-Tae Kim$^1$

Abstract

Background: Hybrid PET/optical imaging provides quantitative and complementary information for diagnosis of tumors. Herein, we developed a $^{64}$Cu-labeled AlexaFluor 680-streptavidin (AF)SAv/biotin-based dimeric cyclic RGD peptide (RGD$_2$) for hybrid PET/optical imaging of integrin $\alpha_V\beta_3$ expression.

Methods: $^{64}$Cu-1,4,7,10-tetraazacyclododecane-$N,N',N''$-$N''''$-tetraacetic acid (DOTA)-(AF)SAv/biotin-PEG-RGD$_2$ was prepared by formation of a complex comprising DOTA-(AF)SAv and biotin-PEG-RGD$_2$, followed by radiolabeling with $^{64}$Cu. Receptor binding studies of DOTA-(AF)SAv/biotin-PEG-RGD$_2$ were performed using U87MG cells and $^{125}$I-RGDyK as the radioligand, and cellular uptake studies of $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ were also performed. MicroPET imaging followed by optical imaging of U87MG tumor-bearing mice was acquired after injection of the hybrid probe, and region of interest (ROI) analysis of tumors was performed. Ex vivo PET/optical imaging and biodistribution studies of the major tissues were performed after the in vivo imaging, and immunofluorescence staining of the tumor tissue sections was carried out.

Results: $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was prepared in 52.1 ± 5.4 % radiochemical yield and with specific activity of 1.0 ± 0.1 GBq/mg. Receptor binding studies showed that DOTA-(AF)SAv/biotin-PEG-RGD$_2$ had higher binding affinity for integrin $\alpha_V\beta_3$ than RGD$_2$, reflecting a possible polyelectivity effect. Moreover, the hybrid probe revealed time-dependent uptake by U87MG cells. In a microPET/optical imaging study, the hybrid probe demonstrated high accumulation in tumors; ROI analysis revealed 2.7 ± 0.2 % ID/g at 1 h and 4.7 ± 0.2 % ID/g at 21 h after injection, and subsequently acquired optical images showed tumors with strong fluorescence intensity. Ex vivo PET/optical images of the major tissues confirmed the in vivo imaging data, and biodistribution studies demonstrated high and specific uptake in tumors (4.8 ± 0.1 % ID/g). Immunofluorescence staining showed the formation of new blood vessels in tumor tissues, suggesting that the tumor uptake was due to specific binding of the hybrid probe to integrin $\alpha_V\beta_3$ expressed on tumor cells.

Conclusions: These results indicate that a $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ is able to provide quantitative information on hybrid PET/optical imaging of integrin $\alpha_V\beta_3$ expression.

Keywords: Streptavidin/biotin, Dimeric RGD peptide, $^{64}$Cu, Integrin $\alpha_V\beta_3$, Hybrid PET/optical imaging
Background
Demand for hybrid imaging probes has been growing with advances in hybrid imaging systems such as PET/CT, SPECT/CT, and PET/MRI, and expansion of their clinical uses [1]. PET provides sensitive and quantitative information, and moreover, PET probes are easily translated for clinical use compared with probes used for other modalities [2]. However, PET has the disadvantage of low spatial resolution. MRI offers the highest spatial resolution but has low sensitivity [2]. Optical imaging has the advantages of real-time imaging with high sensitivity and can potentially be used in intraoperative image-guided surgery [2, 3]. However, it is mainly limited to small animal imaging due to low depth penetration. Therefore, hybrid imaging, by compensating for the drawbacks of single imaging modalities, is more accurate and allows for earlier diagnosis of diseases. This has spurred the development of hybrid imaging probes containing diverse functionalities for application in hybrid PET/optical, PET/MR, and other combinations of imaging modalities.

To develop hybrid imaging probes, nanoparticles are commonly used as platforms because of the ease of addition of diverse functional groups including tumor-targeting compounds. For tumor angiogenesis targeting, cyclic Arg-Gly-Asp (RGD) peptides, selective antagonists of integrin $\alpha_v\beta_3$, have been radionuclide labeled with various radioisotopes. The most well-characterized ligand, $^{18}$F-labeled galacto-RGD peptide, has shown promise for tumor imaging of melanoma M21 tumor-bearing mice and diagnosis of cancer patients [4, 5]. With its longer half-life, $^{64}$Cu-labeled RGD peptide showed prolonged tumor uptake in MDA-MB-435 tumor-bearing mice [6]. In addition, PEGylation of RGD peptides improved in vivo pharmacokinetics; $^{64}$Cu-labeled PEGylated RGD peptide accumulated in tumors at early time points and rapidly washed out from the blood of U87MG tumor-bearing mice compared with $^{64}$Cu-labeled RGD peptide [7, 8]. Multimeric RGD peptides, such as $^{64}$Cu-labeled RGD dimer and tetramer, were shown to possess not only higher integrin binding affinity compared with the corresponding monomer but also prolonged tumor retention and increased renal excretion in tumor-bearing mice, which were possibly attributed to a polyvalency effect [9, 10]. Other dimeric RGD peptides, labeled with $^{18}$F, $^{68}$Ga, and $^{99m}$Tc, have also been shown to have superior in vivo properties than their corresponding monomers [11–14].

Nanoparticles such as liposomes, quantum dots, gold nanoparticles, carbon nanotubes, and others have been conjugated with RGD peptides and utilized for hybrid imaging or improved tumor targeting. $^{111}$In-DTPA-labeled liposomes conjugated with RGD peptide were designed for hybrid SPECT/MR imaging of integrin $\alpha_v\beta_3$. Although $^{111}$In-labeled liposomes exhibited low tumor uptake in U87MG tumor-bearing mice, Gd-labeled liposomes were taken up by the tumors of both U87MG and M21 tumor-bearing mice, based on R1 values [15]. $^{64}$Cu-labeled quantum dots (Qdots) modified with RGD peptides were developed for PET and near-infrared fluorescence (NIRF) imaging, and the tumor vasculature was visualized by both PET and ex vivo NIRF imaging [16]. In another study, RGD peptides and DOTA were conjugated to polyanionic acid-coated iron oxide nanoparticles, which were then labeled with $^{64}$Cu. Hybrid PET/MR imaging of the particles in U87MG tumor-bearing mice showed integrin $\alpha_v\beta_3$ expression in the tumor [17]. $^{125}$I-labeled RGD-PEG-gold nanoparticles were prepared by conjugating PEG to the gold particles and RGD peptide to PEG, and then finally radiolabeling the particles with $^{125}$I. RGD-PEG-gold nanoparticles exhibited much higher binding affinity for integrin $\alpha_v\beta_3$ on U87MG cells than free RGDyC peptide. SPECT/CT images of U87MG tumor-bearing mice showed fast tumor uptake of the gold particles [18]. Single-walled carbon nanotubes have also been used as a platform for tumor angiogenesis imaging; carbon nanotubes coated with RGD- and DOTA-conjugated PEG-phospholipids were labeled with $^{64}$Cu, and then the resulting nanotubes had a high tumor uptake in U87MG tumor-bearing mice. Ex vivo Raman spectroscopy data of the major tissues confirmed the microPET imaging data [19].

Previously, we and others showed that a streptavidin (SAv) and biotin complex can serve as a useful platform for the development of hybrid imaging probes due to the strong interaction between SAv and biotin, with a dissociation constant of approximately $10^{-14}$ M [20]. Examples of these probes include $^{99m}$Tc-HYNIC-labeled quantum dots (Qdots)-SAv/biotin-PEG-EGF, SAv/three biotinylated $^{111}$In-DOTA, Cy5.5 and anti-Her2 antibody, and $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-VEGF $^{121}$ [21–23]. Unlike most nanoparticles, antibody-conjugated SAv and $^{99}$Y-DOTA-biotin have been used clinically for pretargeted radioimmunotherapy, which was shown to be safe [24].

In this study, we extended application of the SAv/biotin platform to the development of an E(cycl(cRGDYK))$_2$ (RGD$_2$)-based hybrid imaging probe for tumor angiogenesis imaging. Therefore, $^{64}$Cu-DOTA-(AlexaFluor680; AF)SAv/biotin-PEG-RGD$_2$ was prepared and evaluated for hybrid PET/optical imaging of integrin $\alpha_v\beta_3$ receptor expression in U87MG tumor-bearing mice.

Methods
Materials and equipment
RGD$_2$ was purchased from Peptide International (Louisville, KY, USA), biotin-PEG(3400)-NHS ester was from Nanocs (New York, NY, USA), (AF)SAv was from Life Technologies (Carlsbad, CA, USA), and DOTA-NHS ester was from Macrocyclcs (Dallas, TX, USA). $^{64}$CuCl$_2$ was kindly provided by KIRAMS (Seoul, Korea). PD-10 columns were purchased from Amersham Biosciences.
(Piscataway, NJ, USA), Amicon filters were from Milli-pore (Billerica, MA, USA), and spin columns were from Thermo Scientific (Rockford, IL, USA). Chelex 100 resin (50–100 mesh) and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), and BCA protein assay kits were from Pierce (Rockford, IL, USA). All buffers used for synthesis and radiolabeling were pretreated with Chelex 100 resin to ensure that they were metal-free. Matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry was performed on a Voyager-DETM STR Biospectrometry Workstation (Applied Biosystems, Foster City, CA, USA). Purification and analysis of products were performed by HPLC (Thermo Scientific, Waltham, MA, USA), and eluates were monitored using a UV detector (218 nm).

Radioactivity was measured using a dose calibrator (Biodex Medical Systems, Shirley, NY, USA), and tissue radioactivity was counted using an automatic gamma counter (PerkinElmer, Waltham, MA, USA). MicroPET and optical images were acquired at the Center for Molecular and Cellular Imaging, Samsung Biomedical Research Institute (SBRI, Seoul, Korea) using an Inveon microPET/CT scanner (Siemens Medical Solutions, Malvern, PA, USA) and a Xenogen IVIS Spectrum (Caliper Life Sciences, Hopkinton, MA, USA), respectively.

Preparation of DOTA-(AF)SAv
(AF)SAv (1.3 mg) and 20 equivalents of DOTA-NHS ester (400 μg, 481.9 nmol) were dissolved in 800 μL of 0.1 M sodium carbonate buffer (pH 8.5), which was then stirred at room temperature for 18 h in the dark. At the end of the reaction, the reaction mixture was purified using a PD-10 column, concentrated using an Amicon filter (cut-off: 10 kDa), and then lyophilized. DOTA-(AF)SAv was obtained at 97.3 % yield, quantified using a BCA protein assay kit, and then analyzed by MALDI-TOF mass spectrometry.

Preparation of biotin-PEG-RGD
RGD (1.7 mg, 1.3 μmol) and biotin-PEG(3400)-NHS ester (2.4 mg, 0.6 μmol) were dissolved in 500 μL of 0.1 M sodium carbonate buffer (pH 8.5), which was then stirred at room temperature for 19 h. At the end of the reaction, the reaction mixture was purified using a HPLC using a C18 column (YMC, 5 μm, 10 × 250 mm) with sequential programs using a mixture of 0.1 % trifluoroacetic acid (TFA) in water and CH₃CN. The first isocratic program was a 90:10 mixture over 10 min, and the second gradient program was from a 90:10 mixture to a 35:65 mixture over 30 min. The flow rate was 3 mL/min. After lyophilization, biotin-PEG-RGD was analyzed by MALDI-TOF mass spectrometry.

Preparation of ⁶⁴Cu-DOTA-(AF)SAv/biotin-PEG-RGD
Biotin-PEG-RGD (91.2 μg, 18.2 nmol) dissolved in acetate buffer (pH 6) was added to DOTA-(AF)SAv (201.9 μg, 3.6 nmol) in the same buffer. The reaction mixture (total volume of 200 μL) was stirred at room temperature for 1 h, and then incubated with ⁶⁴CuCl₂ (377 MBq) at 40 °C for 30 min with constant shaking. Unreacted ⁶⁴CuCl₂ and biotin-PEG-RGD in the reaction mixture were removed by centrifugation using a spin column (molecular weight (mw) cut-off 7 kDa).

In a separate experiment, an aliquot of DOTA-(AF)SAv/biotin-PEG-RGD was purified using a spin column (cut-off 7 kDa) and its purity was determined by HPLC using a Superdex™ 75 GL column (10 × 300 mm, GE Healthcare Life Sciences, Marlborough, MA, USA) and 0.01 M phosphate buffer as the eluent at a flow rate of 0.7 mL/min.

Serum stability
⁶⁴Cu-DOTA-(AF)SAv/biotin-PEG-RGD (98.4 MBq) in 0.01 M PBS (pH 7.4) was added to 50 % fetal bovine serum (FBS; Gibco, Brooklyn, NY, USA) and incubated at 37 °C for 0, 1, 3, 16, and 24 h. At the indicated time points, each sample was loaded onto a PD-10 column, and fractions were eluted using PBS (pH 7) and counted using a dose calibrator.

Cell integrin receptor binding
The integrin α₅β₃ receptor binding study was performed using a previously reported procedure with a slight modification [25]. ¹²⁵I-RGDyK was used as the radioligand and prepared immediately before use. U87MG cells (2 × 10⁵ cells/100 μL) cultured in minimum essential media (MEM; Gibco) were re-suspended in binding buffer (20 mM Tris–HCl buffer with 150 mM NaCl, 2 mM CaCl₂, 1 mM MgCl₂, 1 mM MnCl₂, and 0.1 % bovine serum albumin (BSA); pH 7.4). ¹²⁵I-RGDyK (2.7 kBq/80 μL of binding buffer) was added to tubes containing U87MG cells in the presence of different concentrations (0.1, 1, 10, 10², 10³, and 10⁵ nM; 20 μL) of either DOTA-(AF)SAv/biotin-PEG-RGD or RGD at room temperature for 1 h. After incubation, the cells were washed three times with PBS for 5 min, re-suspended with PBS (1 mL), and then counted using a gamma counter. All experiments were performed in triplicate. IC₅₀ values were determined using GraphPad Prism software 5.

Cellular uptake
U87MG cells were cultured in MEM supplemented with 10 % FBS, streptomycin (100 μg/mL), and penicillin (100 units/mL). Cells were maintained at 37 °C in a humidified 5 % CO₂ incubator. U87MG cells were seeded in 12-well plates at 5 × 10⁵ cells/well and cultured for 2 days. ⁶⁴Cu-DOTA-(AF)SAv/biotin-PEG-RGD (111 kBq/2 μL) was added to each well, and the cells in a total volume of 0.5 mL were incubated at 37 °C for 1, 2, 16, and 21 h. After incubation, the cells were washed three times with PBS. Cell lysis was then carried out using 0.1 N NaOH,
and the resulting lysate was counted using a gamma counter. For the blocking study, cells were incubated with the hybrid probe in the presence of RGD$_2$ (10 μM) at 37 °C for 21 h and then treated as described above. All experiments were performed in triplicate.

**Ethics statement**

This study was reviewed and approved by the Institutional Animal Care and Use Committee of SBRI. SBRI is an Association for Assessment and Accreditation of Laboratory Animal Care International accredited facility and abide by the Institute of Laboratory Animal Resources guide.

**In vivo microPET/optical imaging**

U87MG tumor-bearing mice were prepared by subcutaneously inoculating U87MG cells (5 $\times$ 10³) into the right hind legs of 5-week-old BALB/c nude mice (male). When tumor size reached 407.4 ± 58.6 mm$^3$ at 3 weeks after inoculation, the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ (6.9 ± 0.3 MBq/200 μL) was injected intravenously without ($n = 3$) or with RGD$_2$ (20 mg/kg, $n = 3$) through the tail vein. MicroPET static images were acquired for 10 min at 1, 2, 16, and 21 h after injection. Immediately after microPET imaging, optical images of the mice were acquired (excitation: 675 nm, emission 720 nm) for 1 s.

The images obtained were reconstructed using three-dimensional ordered subset expectation maximization and then processed using Siemens Inveon Research Workplace 4.2. Regions of interest (ROIs) were drawn over tumors in the right legs, and the average signal levels in the ROIs were measured. Data are expressed as percent injected dose per gram of tissue (% ID/g). ROIs of optical images were drawn over tumors, and signal levels were measured using Living Image 3.2 software. These data are presented as photons per second per square centimeter per steradian (photons/s/cm$^2$/sr).

**Ex vivo imaging and biodistribution studies**

At the end of the in vivo microPET/optical imaging study, mice were sacrificed, and major tissues (heart, lungs, liver, spleen, kidneys, intestines, muscle, and tumor) were separated immediately and subjected to ex vivo imaging (microPET, 10-min static scan; optical imaging, 1-s exposure). ROIs of ex vivo images were drawn around each tissue, and the average signal level in the ROI was measured. For the biodistribution study, the tissues of interest and blood were then weighed and counted, and data are expressed as percent injected dose per gram of tissue.

**Immunofluorescence staining**

Tumor tissues obtained after in vivo imaging were fixed in 4 % paraformaldehyde overnight. Specimens were then dehydrated in graded ethanol, embedded in paraffin, and sectioned at 5 μm on a Reichert microtome. The sections were blocked with 1 % BSA in PBS for 30 min and then incubated with goat anti-β3 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit anti-VEGFR2 antibodies (1:100; Santa Cruz Biotechnology) overnight at 4 °C. Subsequently, sections were stained with FITC-labeled anti-goat and rhodamine-labeled anti-rabbit antibodies (1:200; Santa Cruz Biotechnology). Hoechst 33342 (1 μg/mL; Cell Signaling Technology, Danvers, MA, USA) was used to stain the cell nuclei of tumor tissues. Stained tissue sections were examined under a microscope ($\times$200; Nikon Eclipse 80i).

**Statistical analysis**

Data were analyzed with unpaired, two-tailed Student’s $t$ tests. Differences at the 95 % confidence level ($P < 0.05$) were considered statistically significant.

**Results**

**Preparation of DOTA-(AF)SAv and biotin-PEG-RGD$_2$**

DOTA-(AF)SAv prepared from (AF)SAv and DOTA-NHS ester was readily purified using a size-exclusion column. MALDI-TOF mass spectrometric analysis indicated that the average number of DOTA molecules conjugated to (AF)SAv was 3.8 ± 0.6. In contrast, to prepare biotin-PEG-RGD$_2$, excess amounts (2 equivalents) of RGD$_2$ were used to consume as much biotin-PEG-NHS ester as possible, as this NHS ester eluted close to biotin-PEG-RGD$_2$ on HPLC. The resulting biotin-PEG-RGD$_2$ was purified by HPLC, but not using a size-exclusion column because of its similarity in molecular weight to the biotin-PEG-NHS ester. Biotin-PEG-RGD$_2$ was obtained at 87.1 ± 8.1 % yield and identified by MALDI-TOF mass spectrometry: [M + H]$^+$ [M + H]$^+$ calcd. 5023.77, C$_{22}$H$_{413}$N$_{22}$O$_{98}$S; found 5024.57.

**Preparation of $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$**

Purity of a DOTA-(AF)SAv/biotin-PEG-RGD$_2$ complex after spin column purification was confirmed by HPLC using a Superdex™ 75 GL column (Fig. 1a, b). To reduce the requirement for two-step purification comprising DOTA-(AF)SAv/biotin-PEG-RGD$_2$ purification using a spin column and $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ purification using a PD-10 column, the hybrid probe was prepared in a two-step reaction and finally purified; DOTA-(AF)SAv and biotin-PEG-RGD$_2$ were mixed at a ratio of 1 to 5, which was then labeled with $^{64}$Cu, and finally the hybrid probe was purified using a spin column. Non-decay-corrected radiochemical yield of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was 52.1 ± 5.4 % and its specific activity was 1.0 ± 0.1 GBq/mg.
Serum stability

In vitro serum stability of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was measured by incubating the hybrid probe in 50 % serum for 24 h. The results demonstrated that $^{64}$Cu remained stable on the hybrid probe after the 24-h incubation, showing 96.4 % radioactivity at 1 h, 97.8 % at 3 h, 98.1 % at 16 h, and 97.6 % at 24 h relative to a value of 100 % radioactivity at 0 h (Fig. 2).

Cell integrin receptor binding

Receptor binding affinity measurements of DOTA-(AF)SAv/biotin-PEG-RGD$_2$ and RGD$_2$ were performed using U87MG cells and $^{125}$I-RGDyK as the radioligand. IC$_{50}$ values of DOTA-(AF)SAv/biotin-PEG-RGD$_2$ and RGD$_2$ were 12.1 ± 4.2 nM and 37.5 ± 18.3 nM, respectively, indicating that the former had higher binding affinity for integrin $\alpha_V\beta_3$ than RGD$_2$ (Fig. 3).

Cellular uptake

Cellular uptake of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ increased in a time-dependent manner from 100.0 % at 1 h to 298.5 % at 21 h (Fig. 4a). In the blocking study, the cellular uptake decreased to 72.2 % in the presence of RGD$_2$ (10 $\mu$M), indicating specific binding of the hybrid probe to the integrin $\alpha_V\beta_3$ expressed on tumor cells (Fig. 4b).

MicroPET/optical imaging

In vivo microPET and optical imaging of U87MG tumor-bearing mice showed high uptake of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ in the liver, spleen, and tumor (Fig. 5a). ROI values of tumor tissues were 2.7 ± 0.2 % ID/g at 1 h, 2.8 ± 0.2 % ID/g at 2 h, 4.4 ± 0.2 % ID/g at 16 h, and 4.7 ± 0.2 % ID/g at 21 h (Fig. 5e). In the blocking study, tumor uptake was inhibited by 30.3 % in the presence of RGD$_2$ (20 mg/kg) at 16 h after injection (Fig. 5b, e). In optical images, strong fluorescence signals were detected in the liver and tumor, which was a similar uptake pattern to that observed in the PET images (Fig. 5c, d). ROI values of tumor tissues revealed fluorescence signals of (3.7 ± 0.2) $\times$ 10$^8$ photons/s/cm$^2$/sr at 2 h, (6.0 ± 0.2) $\times$ 10$^8$ photons/s/cm$^2$/sr at 16 h, and (6.7 ± 0.3) $\times$ 10$^8$ photons/s/cm$^2$/sr at 21 h. In the presence of RGD$_2$, signal intensity decreased to (4.9 ± 0.2) $\times$ 10$^8$ photons/s/cm$^2$/sr at 21 h (Fig. 5f).

Ex vivo imaging and biodistribution studies

Ex vivo PET and optical imaging carried out immediately after in vivo imaging demonstrated high signal intensity in the liver, spleen, and tumor, consistent with the in vivo imaging data (Fig. 6a–d). The ROI values of ex vivo PET images were 25.4 ± 3.1 % ID/g in the liver, 22.4 ± 1.9 % ID/g
in the spleen, 5.0 ± 0.1 % ID/g in the tumor, and 0.9 ± 0.1 % ID/g in the muscle. In the blocking study, the tumor ROI value was inhibited by 34.9 %. Similarly, ROI analysis of ex vivo optical images showed (16.0 ± 1.0) × 10^7 photons/s/cm^2/sr in the liver, (4.2 ± 0.2) × 10^7 photons/s/cm^2/sr in the spleen, and (3.0 ± 0.2) × 10^7 photons/s/cm^2/sr in the tumor (Fig. 6c). In the blocking group, the fluorescence intensity of the hybrid probe in the tumor decreased to (2.4 ± 0.1) × 10^7 photons/s/cm^2/sr (Fig. 6d).

The biodistribution study performed after ex vivo imaging confirmed the in vivo and ex vivo microPET/optical imaging data; 30.6 ± 1.7 % ID/g in the liver, 26.2 ± 1.1 % ID/g in the spleen, and 4.8 ± 0.1 % ID/g in the tumor (Fig. 7). In the blocking study using RGD_2, tumor uptake of the hybrid probe was inhibited by 32.3 %, whereas there was no significant uptake inhibition in the blood or in other organs (Fig. 7). Tumor-to-muscle and tumor-to-blood uptake ratios obtained with the hybrid probe were 5.0 and 2.3, respectively, whereas ratios in the blocking group were 3.7 and 1.6, respectively, indicating the high specificity of the 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD_2 for integrin α_5β_3.

**Immunofluorescence staining**

Immunofluorescence staining of tumor tissue sections of mice injected with the 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD_2 confirmed expression of β_3 (green) and VEGFR2 (red), and the fluorescence signals from β_3 overlapped with those of VEGFR2 (Fig. 8). This result indicates formation of new blood vessels and tumor angiogenesis in the tumor tissues.

**Discussion**

DOTA-(AF)SAv and biotin-PEG-RGD_2 were prepared via amide bond formation under basic conditions (pH 8.5). Different methods were applied to purify these two molecules due to differences in their molecular weights from reactants; DOTA-(AF)SAv was purified using a PD-10 column, in which the unconjugated DOTA was easily removed because of its low molecular weight (mw 501.49), whereas biotin-PEG-RGD_2 was purified using a centrifugal filter to remove unreacted RGD peptide (mw 1350.43), followed by a reverse-phase HPLC column because of the small difference in molecular weight between biotin-PEG-NHS ester (mw 3790.48) and biotin-PEG-RGD_2 (mw 5025.83). As a result, there were no molecular ion peaks corresponding to both biotin-PEG-NHS ester and RGD peptide detected on MALDI-TOF mass spectrometry, except for the molecular ion peak of biotin-PEG-RGD_2. The key to preparing a SAv/biotin complex is to remove unbound biotin-PEG-RGD_2 after the complex formation. In this study, we used a spin column (mw cut-off 7 kDa) to rapidly remove molecules with a molecular weight less than 7 kDa from the 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD_2.

SAv/biotin complexes have previously been used to develop imaging probes; IRDye800-SAav/biotin-Avi-VEGF_121 and 64Cu-DOTA-(AF)SAv/biotin-PEG-VEGF_121 were shown to have potential for NIRF and PET/optical imaging of VEGF receptor expression, respectively [23, 26]. Moreover, SAav bound to biotinylated 111In-DOTA, Cy5.5, and anti-Her2 antibody showed high tumor uptake in SUM190 tumor-bearing mice [22]. In our study, RGD_2 was conjugated to biotin via PEG to improve its in vivo properties and provide flexibility, while 64Cu-DOTA was directly conjugated to SAav(AF). This imaging probe design may be suitable for hybrid imaging of tumor angiogenesis, because RGD_2 can be used for α_5β_3 receptor binding while the radioisotope and fluorescent dye can be used for PET and optical imaging, respectively. A long PEG chain (mw 3400) was used to allow RGD_2 to gain access to the binding site of the integrin receptor, while the radioisotope and fluorescent dye were conjugated directly to SAav not to interfere with binding of RGD_2 to the integrin receptor. Furthermore, the hybrid probe was stable for 24 h based on an in vitro serum stability study (Fig. 2). In comparison with in vivo PET imaging of 64Cu-DOTA-(AF)SAav without biotin molecules [23], the 64Cu-DOTA-(AF)SAav/biotin-PEG-
RGD$_2$ showed higher tumor uptake that increased in a time-dependent manner, reflecting its long-term stability in vivo.

To evaluate the receptor binding affinity of the probe, U87MG cells, which are known to express high levels of integrin $\alpha_V\beta_3$ [27], were incubated with $^{125}$I-RGDyK in the presence of different concentrations of DOTA-(AF)SAv/biotin-PEG-RGD$_2$ or RGD$_2$. IC$_{50}$ value of DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was 3.1-fold higher than that of RGD$_2$ (Fig. 3). Diverse dimeric and multimeric RGD peptides have been shown to have higher in vitro receptor binding affinity and tumor uptake than monomeric RGD peptides [12, 28]. In this study, four equivalents of the RGD$_2$ peptide were possibly bound to one molecule of SAv because of its tetrameric structure, which might have contributed to the higher binding affinity of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ than the dimeric RGD peptide probably due to a polyvalency effect [9, 10]. Cellular uptake study exhibited that the hybrid probe was taken up by U87MG cells in a time-dependent manner, and that its levels increased 3.0-fold over a 21-h incubation (Fig. 4a). Cellular uptake was inhibited significantly by RGD$_2$,
indicating specificity of the probe to the integrin $\alpha_\text{V}\beta_3$ receptor (Fig. 4b).

In vivo microPET and optical imaging results of $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ demonstrated incremental tumor uptake over time. ROI values of tumor uptake obtained from microPET images increased 1.7-fold over 21 h (Fig. 5a). A similar pattern of tumor uptake was observed in optical images, with uptake increasing 1.8-fold over the same period of time (Fig. 5c). Biodistribution data of this hybrid probe demonstrated higher tumor uptake (4.8 ± 0.1 % ID/g at 21 h after injection) than that of $^{64}$Cu-DOTA-E[(RGDFK)$_2$] in U87MG tumor-bearing mice (<4 % ID/g at 4 h after injection) [9], although $^{64}$Cu-DOTA-E[(RGDyK)$_2$] showed better in vivo kinetics than the D-Phe derivative in MDA-MB-435 tumor-bearing mice [10]. Furthermore, the tumor uptake pattern of $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was similar to that reported for other RGD-conjugated nanoparticles. $^{64}$Cu-DOTA-QDot-RGD showed relatively low tumor uptake at 1 h after injection (less than 1 % ID/g), which then increased to 4.3 ± 0.5 % ID/g at 25 h after injection based on ROI analysis of microPET images [16]. Higher tumor uptake was detected in $^{64}$Cu-labeled RGD-conjugated iron oxide nanoparticles, which were avidly taken up by U87MG tumors of mice (7.9 ± 0.8 % ID/g at 1 h after injection) and increased to 9.8 ± 3.2 % ID/g at 21 h after injection [17]. Another study showed that $^{64}$Cu-DOTA- and RGD-conjugated single-walled carbon nanotubes exhibited significantly high tumor uptake of 10–15 % ID/g at 24 h after injection compared to 3–4 % ID/g uptake of RGD-free nanotubes [19]. The presence of SAv in the hybrid probe may affect tumor uptake, because $^{111}$In-labeled SAv was reported to accumulate in tumors in LS174T tumor mice (4.5 ± 0.2 % ID/g at 5 h after injection) [29]. In our previous study, however, $^{64}$Cu-DOTA-(AF)SAv without biotin molecules showed low tumor uptake (1.6 ± 0.1 % ID/g at 22 h) [23]. Therefore, tumor uptake of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was likely due to the probe itself.

The hybrid probe showed high uptake in the liver and spleen compared with that of $^{64}$Cu-DOTA-E[(RGDFK)$_2$] [9]. This high uptake in the reticuloendothelial system resulted from the presence of the relatively large molecule, SAv, as shown by high liver uptake of $^{64}$Cu-DOTA-(AF)SAv (15.7 ± 0.57 % ID/g at 22 h) [23]. A similar uptake pattern was detected in microPET images of U87MG tumor-

![Fig. 7](image_url) Bioluminescence data of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ in U87MG tumor-bearing mice at 21 h after injection (black) and after co-injection with RGD$_2$ (white). Inset is an enlarged graph showing tumor uptake of the control (black) and blocking (white) groups. I indicates intestine. Values represent mean % ID/g and error bars indicate SD ($n = 3$). ***P < 0.001

![Fig. 8](image_url) Immunofluorescence staining of U87MG tumor tissue sections obtained after microPET/optical imaging. Cell nuclei are shown as blue dots. Magnification x200. Arrows indicate overlay areas.
bearing mice injected with $^{64}$Cu-DOTA-QDot-RGD; liver uptake was higher than 40 % ID/g up to 25 h after injection based on ROI analysis [16]. $^{64}$Cu-labeled RGD-conjugated iron oxide nanoparticles also showed high liver uptake (31.1 ± 2.5 % ID/g at 1 h and 11.7 ± 1.2 % ID/g at 21 h after injection), probably due to the relatively large size of the particles [17]. Similarly, high liver uptake (17~30 % ID/g at 24 h) was also detected in mice injected with $^{64}$Cu-labeled single-walled carbon nanotubes coated with phospholipid-PEG chains conjugated to the RGD peptide [19]. The longer the PEG chain, the lower the liver uptake and the higher the tumor uptake of nanotubes [19]. Therefore, use of longer PEG arms may improve the in vivo properties of the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ by reducing liver uptake. Optical images confirmed the microPET imaging data for the hybrid probe and showed high fluorescence intensity in tumors that increased over time (Fig. 5c, d). While the $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ was taken up by the liver and spleen based on PET imaging, this was not clear from optical images due to the presence of the skeleton and the depth penetration limitations of optical imaging. However, ex vivo optical images revealed that the hybrid probe was taken up by the liver, spleen, and tumor (Fig. 6c, d).

Immunofluorescence staining of tumor tissue sections obtained after microPET/optical imaging demonstrated that $\beta_3$ receptors were highly expressed on endothelial cells (VEGFR2) of blood vessels (Fig. 8). This result suggests that tumor uptake of the hybrid probe was attributable to its binding to integrin $\alpha_v\beta_3$.

Our study showed that both microPET and optical imaging data of $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ in U87MG tumor-bearing mice were in good agreement for monitoring integrin $\alpha_v\beta_3$ expression. This hybrid probe provided real-time detection of tumor as well as quantitative information on tumor and major organs with high specificity and sensitivity. In addition, this hybrid probe may have advantages, because hybrid PET/optical probes may allow for preoperative detection, intraoperative image-guided surgery, and postoperative evaluation of tumors.

Conclusions

We prepared a $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ efficiently using a SAv/biotin complex as a platform. As shown by a receptor binding study, DOTA-(AF)SAv/biotin-PEG-RGD$_2$ exhibited higher binding affinity for the integrin $\alpha_v\beta_3$ than RGD$_2$ peptide, which we attributed to a possible polyvalency effect by four flexible biotin-PEG-RGD$_2$ arms complexed with one SAv core. PET/optical images of U87MG tumor-bearing mice indicated that the hybrid probe accumulated in tumor with prolonged retention over 21 h. These results demonstrate that $^{64}$Cu-DOTA-(AF)SAv/biotin-PEG-RGD$_2$ provides specific and sensitive hybrid PET/optical images for monitoring integrin $\alpha_v\beta_3$ expression, and that a SAv/biotin complex is a useful platform for developing hybrid imaging probes.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CMK prepared the hybrid imaging probe and performed the in vivo studies. HJK performed cell binding and receptor binding studies. GIA produced and supplied $^{64}$Cu$_{68}$, JYC, KHL, and BTK contributed to the design of in vivo studies and provided helpful comments on the results. YSC designed and supervised the study. All authors approved the final manuscript.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF) (grant code: 2011-0030164).

Author details

1. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea. 2. Department of Health Sciences and Technology, SKAST, Sungkyunkwan University, Seoul 06351, Korea. 3. Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.

Received: 12 August 2015 Accepted: 19 October 2015

Published online: 31 October 2015

References

1. Cherry SR. Multimodality in vivo imaging systems: twice the power or double the trouble? Annu Rev Biomed Eng. 2006;8:85–62.
2. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2001;15:545–80.
3. Koenigswarter S, Van Driel PBAA, Snoeks TJA, Kerrebijn JDF, de Jong RJ B, Vahmeijer AL, et al. Optical image-guided cancer surgery: challenges and limitations. Clin Cancer Res. 2013;19:7345–54.
4. Houbner R, Waster HJ, Weber WA, Mang C, Ziegler SL, Goodman SL, et al. Noninvasive imaging of $\alpha_v\beta_3$ integrin expression using $^{19}$F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–5.
5. Beer AJ, Houbner R, Goebel M, Luderscheidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the $\alpha_v\beta_3$-selective tracer $^{18}$F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.
6. Chen X, Park R, Tohme M, Shahnian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer $\alpha_v$-integrin expression using $^{18}$F- and $^{64}$Cu-labeled RGD peptide. Bioconj Chem. 2004;15:41–9.
7. Chen X, Park R, Shahnian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of $^{125}$I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11–9.
8. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzalez-Gomez I, et al. Pegylated Arg-Gly-Asp peptide $^{18}$F labeling and PET imaging of brain tumor $\alpha_v\beta_3$-integrin expression. J Nucl Med. 2004;45:1776–83.
9. Wu Y, Zhang X, Xion Z, Cheng Z, Fisher DR, Liu S, et al. MicroPET imaging of glioma $\alpha_v$-integrin expression using $^{64}$Cu-labeled tetrameric RGD peptide. J Nucl Med. 2006;47:1707–18.
10. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer $\alpha_v$-integrin expression with $^{64}$Cu-labeled dimeric RGD peptide. Mol Imaging Biol. 2004;6:350–9.
11. Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS. Micro-PET imaging of $\alpha_v\beta_3$-integrin expression with $^{18}$F-labeled dimeric RGD peptide. Mol Imaging. 2004;3:96–104.
12. Li ZB, Chen K, Chen X. $^{64}$Cu-labeled multimeric RGD peptides for microPET imaging of integrin $\alpha_v\beta_3$ expression. Eur J Nucl Med Mol Imaging. 2008;35:1100–8.
13. Janssen ML, Oyen WJ, Massuger LF, Flierl CK, Dijkstra I, Edwards DS, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17:641–6.
14. Janssen ML, Oyen WJ, Dijkstra I, Massuger LF, Flierl CK, Edwards DS, et al. Tumor targeting with radiolabeled $\alpha_v\beta_3$ integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:46–51.
15. Rangger C, Helbok A, Sozabowski J, Kremser C, Koeiner G, Prasl R, et al. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Int J Nanomedicine. 2013;8:4659–71.

16. Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007;48:1862–70.

17. Lee HY, Li Z, Chen K, Sosabowski J, Koehler G, Prassl R, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371–9.

18. Kim YH, Jeon J, Hong SH, Rhim WK, Lee YS, Youn H, et al. Tumor targeting and imaging using cyclic RGD PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small. 2011;7:2052–60.

19. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007;2:47–52.

20. Green NM. Avidin. In: Anfinsen CB, Edsall JT, Richard FM, editors. Advances in protein chemistry. New York: Academic Press; 1975. p. 85–133.

21. Jung KH, Cho EY, Park JH, Lee KH. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to Cetuximab therapy. J Nucl Med. 2011;52:1457–64.

22. Liang M, Liu X, Cheng D, Liu G, Dou S, Wang Y, et al. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem. 2010;21:1385–8.

23. Kang CM, Koo HJ, Lee KC, Cho YS, Choi JY, Lee KH, et al. A vascular endothelial growth factor 121 (VEGF$_{121}$)-based dual PET/optical probe for in vivo imaging of VEGF receptor expression. Biomaterials. 2013;34:6839–45.

24. Bretz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 111In-DOTA-biotin. J Nucl Med. 2000;41:1311–40.

25. Park JA, Lee YJ, Kim TJ, Chang Y, Lim SM, Kim KM, et al. Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide. Biochem Biophys Res Commun. 2014;455:246–50.

26. Wang H, Chen K, Niu G, Chen X. Site-specifically biotinylated VEGF$_{121}$ for near-infrared fluorescence imaging of tumor angiogenesis. Mol Pharm. 2009;6:285–94.

27. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin $\alpha$,$\beta$3 expression with $^{18}$F-FRGD2. J Nucl Med. 2006;47:113–21.

28. Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, Dyen WJ, Corstens FH, et al. Improved targeting of the $\alpha$,$\beta$3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34:267–73.

29. Hnatowich DJ, Fritz B, Virzi F, Mandirosson G, Rusckowski M. Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody. Nucl Med Biol. 1993;20:189–95.